argenx to Present Clinical Update on Cusatuzumab at 63rd Annual ASH Meeting

Former TAP Partner

argenx

argenx a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer presented clinical data for cusatuzumab, an investigational SIMPLE Antibody™ targeting CD70, an immune checkpoint target, at the virtual 63rd American Society of Hematology (ASH) Annual Meeting taking place from December 11 – 14, 2021 in Atlanta, GA.

369 Oral Sunday, December 12, 2021: 9:30 AM-11:00 AM Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study